-
Mashup Score: 5
Contact: Nicole Napoli , nnapoli@acc.org, 202-669-1465 People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y 12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 2
Contact: Nicole Napoli , nnapoli@acc.org, 202-669-1465 People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y 12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet
A new study presented at #ACC24 out of @IcahnMountSinai suggests most patients with #cvACS can safely stop Aspirin one month after #PCI. https://t.co/ChHAB7lqCf https://t.co/bVwRwXXrwA